ST-elevation Myocardial Infarction (STEMI)
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Verona PharmaUK - London
1 programMicroplastics and Nanoplastics (MNPs) in Patients With ST-elevation Myocardial Infarction (STEMI)N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
CeleCor Therapeuticszalunfiban
Verona PharmaMicroplastics and Nanoplastics (MNPs) in Patients With ST-elevation Myocardial Infarction (STEMI)
Clinical Trials (2)
Total enrollment: 2,593 patients across 2 trials
A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI
Start: Apr 2021Est. completion: May 20262,463 patients
Phase 3Active Not Recruiting
NCT06965023Verona PharmaMicroplastics and Nanoplastics (MNPs) in Patients With ST-elevation Myocardial Infarction (STEMI)
Microplastics and Nanoplastics (MNPs) in Patients With ST-elevation Myocardial Infarction (STEMI)
Start: Apr 2025Est. completion: Dec 2027130 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 2,593 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.